Despite challenging markets new players are entering the field to advance drug development in the fight against antimicrobial resistance.
SMEs active in antibiotic development are trying to adapt to the uncertain AMR business. Meanwhile, the European IMI AMR accelerator kicked off.
Antibiotic developers struggle with uncertain market conditions, weak reimbursement schemes and low turnover once a drug is approved. Experts are trying to figure out the best way to balance push and pull incentives.
Although it has only been shown to provide partial protection, the first-ever malaria vaccine is in testing in Africa – and there are many more hopefuls in the pipeline. Will we soon eradicate one of the most deadly pathogens in human history?
Tackling the malaria pathogen P. falciparum has been complex, due to rapid development of resistance. A new compound targets liver stages of the parasite and, thus, provides a new mode of action to reduce the population of the parasite.
Its no easy task to develop medications that are effective and safe to use. The pharmaceutical industry loses billions every year due to safety-related attrition during the drug discovery process. For both patients and companies, improving productivity in the area would bring significant benefits. Now novel biomarkers designed to better detect and manage drug-induced organ injury – both preclinically and clinically – could make the process faster, safer and cheaper. tg
Outgoing EU Commissioner for Agriculture Paul Hogan said in April, that the European Commission will exclude member states from the future Common Agricultural Policy (CAP) that do not include the promotion of the bioeconomy in agriculture.
The European Council, the European Parliament, and the outgoing European Commission have agreed upon the priorities and structure of Horizon Europe (2021 to 2027), the next seven-year research and innovation programme of the European Union. This autumn, they will decide on the Parliaments proposal to increase its budget from €100bn to €120bn.
After the birth of the first genome-edited babies in China, regulators, researchers, and bioethics experts seek ways to ban clinical use of germline editing, in order to protect the innovative field from misuse for human enhancement and side effect-prone application forgene correction and human enhancement.
There is a growing demand for more patient-centric drug delivery and improved health-care cost management via self-administration and smart devices. The global drug device combination market is projected to reach nearly US$140m by 2025. Its where the two different worlds of pharmaceutical (GMP) and standardised medical devices collide.Each needs to learn from the other in order to facilitate the regulation process in Europe.